These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28090231)

  • 1. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
    Tahara A; Takasu T
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Tahara A; Takasu T
    Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
    Matsuba I; Kawata T; Iemitsu K; Asakura T; Amemiya H; Ishikawa M; Ito S; Kaneshiro M; Kanamori A; Kubota A; Shinoda K; Takai M; Takuma T; Takihata M; Takeda H; Tanaka K; Matsuzawa Y; Machimura H; Minagawa F; Minami N; Mokubo A; Miyakawa M; Terauchi Y; Tanaka Y
    J Diabetes Investig; 2020 Sep; 11(5):1248-1257. PubMed ID: 32149469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
    Tahara A; Takasu T
    Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Diabetes Ther; 2020 Apr; 11(4):951-964. PubMed ID: 32166619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
    Tahara A; Kondo Y; Takasu T; Tomiyama H
    Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Kashiwagi A; Kazuta K; Yoshida S; Nagase I
    J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
    Takakura S; Takasu T
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):266-273. PubMed ID: 30485488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.